COVI-VAC
Jump to navigation
Jump to search
| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | Attenuated |
| Clinical data | |
| Trade names | CDX-005[1] |
| Routes of administration | Intranasal |
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
.svg){kind=small} COVID-19 portal |
COVI-VAC (codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc.[2] It is a live attenuated vaccine administered intranasally and requires just one dose. It is currently in Phase 1 clinical trials, involving 48 participants which runs from December 2020 to June 2021.[3]
References[edit]
- ^ "Serum Institute starts manufacturing Codagenix's nasal COVID-19 vaccine". mint. 22 September 2020.
- ^ "COVI-VAC for SARS-CoV-2 (COVID-19)". Codagenix, Inc. Retrieved 8 June 2021.
- ^ "Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19". ClinicalTrials.gov. United States National Library of Medicine. Retrieved 8 June 2021.
 |
Scholia has a profile for COVI-VAC (Q107229181). |
.png){kind=small} | This article about the COVID-19 pandemic is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it. |